A recent systematic review and meta-analysis addressing the irAEs of anti-PD-1 and anti-PD-L1 mAbs, including relevant information from ClinicalTrials.gov, showed that hypothyroidism was the most common organ-specific adverse event among patients exposed to anti-PD-1 mAbs. This evidence concerns the gene CD274 and hypothyroidism.